Clinical Trial Search

Primary: Change in Dizziness Handicap Inventory (DHI) Questionnaire Score — 10.25; 49.6 units on a scale

Primary: Number of Vertigo Episodes — 5.41; 5.03; 13.78 number of episodes — p=<0.001

Primary: Vestibular "Endolymphatic Hydrops (EH)" — 0; 4; 2 participants

Primary: Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group — 18.88; 18.00; 13.50; 4.57 Average Total Number of Vertigo Attacks — p=0.5618

Primary: The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12). — 2.191; 2.415 Definitive Vertigo Day — p=0.623

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 19; 20; 20; 15 Participants

Primary: 28-Day Average DVD at Week 12 (Month 3) — 2.869; 3.577 DVD — p=0.312

Primary: Vertigo Attacks — 16.4; 19.93; 1.6; 2.5 Vertigo Attacks — p=0.271

Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level

Primary: Subjective Symptoms Self-report of Overall Severity — 5.2; 5.2; 3.2; 2.1 score on a scale

Primary: Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE) — 43; 79; 104; 61 participants

Primary: Headache Disability Inventory (HDI) — 14.3 score on a scale — p=<.0001

Primary: Dizziness Handicap Inventory — -12.0; -13.2 score on a scale

Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466

Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97

Primary: Peripheral Vestibular Function (Vestibulo-ocular Reflex/Semicircular Canal): Caloric Weakness — 8.8; 14.7; 12.3; 7.1 percentage of caloric weakness

Primary: Hearing Improvement — 30.7; 28.7 dB

Primary: Dizziness Handicap Inventory — -17.5; -3.7; -8.4; -10.1 score on a scale — p=0.0439

Primary: Likert Scale for Satisfaction — 9; 9 units on a scale

Primary: Root Mean Square Velocity Anterior-posterior [AP] in cm/s (RMSV) — 3.59; 3.30; 3.07 cm/s — p=0.005

Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale

Primary: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild — 50; 73 Episodes — p=<0.33

Primary: Change in Sensory Organization Test (SOT) Composite Score (Score After Retraining Minus Score at Baseline) — 8.8 SOT composite score

Primary: Change From Baseline in the Nonmotor Symptom Severity Scale (NMSS) — -33.5; -2.0 change in scale total score — p=0.0089

Primary: Vestibulo-ocular Reflex Gain Ratio — 1.15 unitless gain ratio — p=<0.001

Primary: Tinnitus Distress Rating — 5.71; 5.82; 5.36; 5.46 units on a scale

Primary: To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease — 7 responders

Primary: Change in Consonant-Nucleus-Consonant (CNC) Words Scores Over Time — 23.6; 22; 18.8; 42.7 Percentage of words correct

Primary: Average Threshold Shift at 4 kHz in Both Ears — 3.94; 3.4; 2.77; 2.03 decibels — p=0.58

Primary: Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Pre Test to Post Test 1 Sensory Organization Test (SOT)…